Are Surrogate Markers Adequate to Assess Cardiovascular Disease Drugs?
- 25 August 1999
- journal article
- controversies
- Published by American Medical Association (AMA) in Jama-Journal Of The American Medical Association
- Vol. 282 (8), 790-795
- https://doi.org/10.1001/jama.282.8.790
Abstract
Opinion from JAMA — Are Surrogate Markers Adequate to Assess Cardiovascular Disease Drugs?Keywords
This publication has 12 references indexed in Scilit:
- A Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart FailureNew England Journal of Medicine, 1998
- What Have We Learned From the Calcium Channel Blocker Controversy?Circulation, 1998
- Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertensionThe Lancet, 1997
- Surrogates, Semantics, and Sensible Public PolicyCirculation, 1997
- Rationale and Design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)American Journal of Hypertension, 1996
- Long‐Term Survival and Use of Antihypertensive Medications in Older PersonsJournal of the American Geriatrics Society, 1995
- Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart FailureJAMA, 1995
- Diuretic Therapy for Hypertension and the Risk of Primary Cardiac ArrestNew England Journal of Medicine, 1994
- Reminiscences of the Veterans Administration trial of the treatment of hypertension.Hypertension, 1990
- Design of Trials to Assess Safety and Effectiveness in Rx of CHFPublished by Springer Science and Business Media LLC ,1987